ESR1 Methylation Measured in Cell-Free DNA to Evaluate Endocrine Resistance in Metastatic Breast Cancer Patients

ESR1 methylation was proposed as mechanism for endocrine resistance in metastatic breast cancer patients. To evaluate its potential as a minimally invasive biomarker, we investigated the feasibility of measuring ESR1 methylation in cell-free DNA (cfDNA) and its association with endocrine resistance....

Descripción completa

Detalles Bibliográficos
Autores principales: Bos, Manouk K., Deger, Teoman, Sleijfer, Stefan, Martens, John W. M., Wilting, Saskia M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9142900/
https://www.ncbi.nlm.nih.gov/pubmed/35628441
http://dx.doi.org/10.3390/ijms23105631

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9142900/
https://www.ncbi.nlm.nih.gov/pubmed/35628441
http://dx.doi.org/10.3390/ijms23105631

Ejemplares similares